Key Points Novo Nordisk could strengthen its obesity pipeline by buying out Kailera Therapeutics and Viking Therapeutics. These two biotechs boast highly promising mid and late-stage programs. Even without acquisitions, Novo could have a significantly improved approved portfolio within a few years. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) has a problem. The company generates most of its revenue from its diabetes and obesity products, but stiff competition from Eli Lilly (NYSE: LLY) in these markets has significantly disrupted its business. To make matters worse, other drugmakers will launch brand-new products in this field over the next few years. Novo Nordisk could struggle even more in a more competitive environment.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.